

1. Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. *Blood* 1996;87:3633–3639.
2. Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. *N Engl J Med* 1989;321:784–789.
3. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. *N Engl J Med* 1997;336:897–904.
4. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. *Blood* 2000;95:1588–1593.
5. Rowlings PA, Curtis RE, Passweg J, et al. Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation. *J Clin Oncol* 1999;17:3122–3127.
6. Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. *Blood* 2009;113:1175–1183.
7. Leisenring W, Friedman DL, Flowers ME, et al. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. *J Clin Oncol* 2006;24:1119–1126.
8. Schwartz JL, Kopecky KJ, Mathes RW, et al. Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation. *Radiat Res* 2009;171:155–163.
9. Friedman DL, Rovo A, Leisenring W, et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. *Blood* 2008;111:939–944.
10. Cohen A, Rovelli A, Merlo DF, et al. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study. *J Clin Oncol* 2007;25:2449–2454.
11. Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. *J Clin Oncol* 2001;19:464–471.
12. Witherspoon RP, Deeg HJ. Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia. *Haematologica* 1999;84:1085–1087.
13. Bhatia S, Robison LL, Francisco L, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. *Blood* 2005;105:4215–4222.
14. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. *Blood* 2002;100:2292–2302.
15. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, et al. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. *Blood* 2002;99:1909–1912.
16. Gilliland DG, Gribben JG. Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation. *Biol Blood Marrow Transplant* 2002;8:9–16.
17. Friedberg JW, Neuberg D, Stone RM, et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. *J Clin Oncol* 1999;17:3128–3135.
18. Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. *Blood* 2003;101:2015–2023.
19. Bhatia R, Van Heijzen K, Palmer A, et al. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma. *J Clin Oncol* 2005;23:6699–6711.
20. Graubert TA, Payton MA, Shao J, et al. Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. *PLoS One* 2009;4:e4583.
21. Lane SW, Sykes SM, Al-Shahrour F, et al. The *Apc*(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS. *Blood* 2010;115:3489–3497.
22. Wong JC, Zhang Y, Lieu KH, et al. Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies. *Blood* 2010;115:4524–4532.
23. Downing JR. AML1/CBFbeta transcription complex: its role in normal hematopoiesis and leukemia. *Leukemia* 2001;15:664–665.
24. Qian Z, Joslin JM, Tennant TR, et al. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. *Chem Biol Interact* 2010;184:50.
25. Libura J, Slater DJ, Felix CA, et al. Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion. *Blood* 2005;105:2124–2131.
26. Side LE, Curtis NP, Teel K, et al. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. *Genes Chromosomes Cancer* 2004;39:217–223.
27. Knight JA, Skol AD, Shinde A, et al. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. *Blood* 2009;113:5575–5582.
28. Funk RK, Maxwell TJ, Izumi M, et al. Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic mice. *Blood* 2008;112:1434–1442.
29. Allan JM, Wild CP, Rollinson S, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. *Proc Natl Acad Sci U S A* 2001;98:11592–11597.
30. Ellis NA, Huo D, Yildiz O, et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. *Blood* 2008;112:741–749.
31. Casorelli I, Offman J, Mele L, et al. Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. *DNA Repair (Amst)* 2003;2:547–559.
32. Seedhouse CH, Das-Gupta EP, Russell NH. Methylation of the hMLH1 promoter and its association with microsatellite instability in acute myeloid leukemia. *Leukemia* 2003;17:83–88.
33. Seedhouse C, Faulkner R, Ashraf N, et al. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. *Clin Cancer Res* 2004;10:2675–2680.
34. Matullo G, Palli D, Peluso M, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. *Carcinogenesis* 2001;22:1437–1445.
35. Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. *Environ Health Perspect* 2003;111:1843–1850.
36. Seedhouse C, Bainton R, Lewis M, et al. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. *Blood* 2002;100:3761–3766.
37. Allan JM, Smith AG, Wheatley K, et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. *Blood* 2004;104:3872–3877.
38. Chakraborty S, Sun CL, Francisco L, et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. *J Clin Oncol* 2009;27:791–798.
39. Hackett JA, Feldser DM, Greider CW. Telomere dysfunction increases mutation rate and genomic instability. *Cell* 2001;106:275–286.
40. Voermans C, Kooi ML, Rodenhuis S, et al. In vitro migratory capacity of CD34+ cells is related to hematopoietic recovery after autologous stem cell transplantation. *Blood* 2001;97:799–804.
41. Dittel BN, LeBien TW. Reduced expression of vascular cell adhesion molecule-1 on bone marrow stromal cells isolated from marrow transplant recipients correlates with a reduced capacity to support human B lymphopoiesis in vitro. *Blood* 1995;86:2833–2841.
42. Domenech J, Roingard F, Herault O, et al. Changes in the functional capacity of marrow stromal cells after autologous bone marrow transplantation. *Leuk Lymphoma* 1998;29:533–546.
43. Cachaco AS, Carvalho T, Santos AC, et al. TNF-alpha regulates the effects of irradiation in the mouse bone marrow microenvironment. *PLoS One* 2010;5:e8980.
44. Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. *Nature* 2010;464:852–857.
45. Yeoh EJ, Williams K, Patel S, et al. Expression profiling of pediatric acute lymphoblastic leukemia (ALL) blasts at diagnosis accurately predicts both the risk of relapse and of developing therapy-induced acute myelogenous leukemia (AML). *Blood* 2001;98:433A.
46. Qian Z, Fernald AA, Godley LA, et al. Expression profiling of CD34+ hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. *Proc Natl Acad Sci U S A* 2002;99:14925–14930.
47. Li L, Li M, Sun CL, et al. Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. *Cancer Cell* 2011;20:591–605.
48. Armand P, Kim HT, DeAngelo DJ, et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. *Biol Blood Marrow Transplant* 2007;13:655–664.
49. Yakoub-Agha I, de La Salmoniere P, Ribaud P, et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. *J Clin Oncol* 2000;18:963–971.
50. Litzow MR, Tarima S, Perez WS, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. *Blood* 2010;115:1850–1857.
51. Lillington DM, Micallef IN, Carpenter E, et al. Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma. *J Clin Oncol* 2001;19:2472–2481.
52. Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. *Blood* 2009;113:4992–5001.
53. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. *Blood* 1999;94:2208–2216.
54. Luo L, Zhang L, Cai B, et al. Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: a single-center experience. *Ann Transplant* 2014;19:6–12.
55. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. *Nat Med* 1996;2:551–555.

56. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. *Lancet* 1995;345:9–13.
57. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. *Blood* 2002;99:4364–4369.
58. Meerbach A, Wutzler P, Hafer R, et al. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. *J Med Virol* 2008;80:441–454.
59. Styczynski J, Einsele H, Gil L, et al. Outcome of treatment of Epstein Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stemcell recipients: a comprehensive review of reported cases. *Transpl Infect Dis* 2009;11:383–392.
60. Majhail NS, Brazauskas R, Rizzo JD, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. *Blood* 2011;117:316–322.
61. Faber P, Fisch P, Waterhouse M, et al. Frequent genomic alterations in epithelium measured by microsatellite instability following allogeneic hematopoietic cell transplantation in humans. *Blood* 2006;107:3389–3396.
62. Strong LC, Stine M, Norsted TL. Cancer in survivors of childhood soft tissue sarcoma and their relatives. *J Natl Cancer Inst* 1987;79:1213–1220.
63. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. *JAMA* 1997;278:1262–1267.
64. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer: The Children's Oncology Group long-term follow-up guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. *J Clin Oncol* 2004;22:4979–4990.
65. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. *Bone Marrow Transplant* 2012;47:337–341.
66. Smith RA, Cokkinides V, von Eschenbach AC, et al. American Cancer Society guidelines for the early detection of cancer. *CA Cancer J Clin* 2002; 52:8–22.
67. Carlson RW, McCormick B. Update: NCCN breast cancer Clinical Practice Guidelines. *J Natl Compr Canc Netw* 2005;3:S7–S11.
68. Socie G, Rizzo JD. Second solid tumors: screening and management guidelines in long-term survivors after allogeneic stem cell transplantation. *Semin Hematol* 2012;49:4–9.
69. Curtis RE, Metayer C, Rizzo JD, et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. *Blood* 2005;105:3802–3811.
70. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N Engl J Med* 2003;348:1625–1638.
71. Ness KK, Bhatia S, Baker KS, et al. Performance limitations and participation restrictions among childhood cancer survivors treated with hematopoietic stem cell transplantation: the bone marrow transplant survivor study. *Arch Pediatr Adolesc Med* 2005;159:706–713.
72. Fraser CJ, Bhatia S, Ness K, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. *Blood* 2006;108: 2867–2873.
73. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. *Blood* 2007; 109:1765–1772.
74. Baker KS, Chow E, Goodman P, et al. Adverse impact of hematopoietic cell transplantation (HCT) on body composition and insulin resistance is associated with increased cardiovascular risk. *Biol Blood Marrow Transplant* 2011;17:S174–S175.
75. Baker KS, DeFor TE, Burns LJ, et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. *J Clin Oncol* 2003;21:1352–1358.
76. Shimada K, Yokozawa T, Atsuta Y, et al. Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis. *Bone Marrow Transplant* 2005;36:115–121.
77. Gallagher G, Forrest DL. Second solid cancers after allogeneic hematopoietic stem cell transplantation. *Cancer* 2007;109:84–92.
78. Socie G, Curtis RE, Deeg HJ, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. *J Clin Oncol* 2000;18:348–357.